COGT vs FRT · $5.75B cap vs rev $1.28B
Cogent Biosciences Inc (COGT) versus FRT (FRT) — a side-by-side from cached financials, not a winner call.
Cogent Biosciences Inc (COGT) is a biotechnology company listed on NASDAQ.
FRT (FRT) common stock.
COGT does not have a complete income-statement cache yet.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
COGT currently screens at market cap $5.75B. FRT currently screens at market cap $0.
Not investment advice. Open the COGT and FRT stock pages for the full models.
Not investment advice.